In view of the evolving use of anti-CCR9 therapies in IBD, these findings support therapeutic exploration in models exhibiting concomitant features of cholangitis and colitis [45], [46]; of particular relevance given that it is the CCR9 positive subset of mucosal T-cells which are implicated in the pathogenesis of PSC [12]. Here, CCR9 is linked to cholangitis.